Event Details

Initial Preliminary Data from Phase 1 SWORD-1 Study of TPX-0046

Apr 05, 2021 at 4:30 PM EDT

ABOUT

Management
Board of Directors
Scientific Advisory Board

PIPELINE

Repotrectinib
TPX-0022
TPX-0046
ALK Inhibitor

OUR SCIENCE

Our Approach
Addressing Resistance
Publications

CLINICAL TRIALS

TRIDENT-1
Compassionate Use

NEWS

Press Releases
Publications

CAREERS

Mission and Values
Our Culture
Opportunities

Terms of Use | Copyright © 2021 Turning Point Therapeutics, Inc. | All Rights Reserved